Category: biotech

.After revealing a period 3 launch based upon positive midstage end results, iTeos and also GSK are lastly sharing the highlights coming from the stage

.Otsuka Drug’s renal illness medicine has reached the primary endpoint of a phase 3 trial by showing in an acting review the reduction of people’

.Bicara Therapeutics and Zenas Biopharma have actually delivered new impetus to the IPO market along with filings that emphasize what newly public biotechs may look

.After increasing $213 million in 2023– one of the year’s most extensive exclusive biotech rounds– Volume Biosciences is actually creating reduces.” Despite our clear medical

.OncoC4 is actually taking AcroImmune– and its own internal scientific production functionalities– under its own wing in an all-stock merger.Each cancer cells biotechs were co-founded

.Zephyrm Bioscience is gusting towards the Hong Kong stock market, submitting (PDF) for an IPO to stake period 3 trials of its cell therapy in

.It’s an extraordinarily busy Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bicara Rehabs all going community with fine-tuned offerings.These days’s 3 Nasdaq

.After showing programs to strike the USA social markets less than a month earlier, Zenas Biopharma and also Bicara Therapeutics have actually arranged the particulars

.4 months after Mandarin gene modifying firm YolTech Therapies took its own cholesterol disease-focused prospect in to the clinic, Salubris Pharmaceuticals has actually protected the

.Three months after exposing that its own respiratory syncytial virus (RSV) precautionary antibody clesrovimab had actually met with approval in a period 2b/3 trial, Merck